These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1575 related articles for article (PubMed ID: 23642924)

  • 1. The United States StuDy for EvalUating EndovasculaR TreAtments of Lesions in the Superficial Femoral Artery and Proximal Popliteal By usIng the Protégé EverfLex NitInol STent SYstem II (DURABILITY II).
    Matsumura JS; Yamanouchi D; Goldstein JA; Pollock CW; Bosiers M; Schultz GA; Scheinert D; Rocha-Singh KJ
    J Vasc Surg; 2013 Jul; 58(1):73-83.e1. PubMed ID: 23642924
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Results of the Protégé EverFlex 200-mm-long nitinol stent (ev3) in TASC C and D femoropopliteal lesions.
    Bosiers M; Deloose K; Callaert J; Moreels N; Keirse K; Verbist J; Peeters P
    J Vasc Surg; 2011 Oct; 54(4):1042-50. PubMed ID: 21636239
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PEACE I all-comers registry: patency evaluation after implantation of the 4-French Pulsar-18 self-expanding nitinol stent in femoropopliteal lesions.
    Lichtenberg M; Kolks O; Hailer B; Stahlhoff WF; Tiefenbacher C; Nolte-Ernsting C; Arjumand J; Wittenberg G
    J Endovasc Ther; 2014 Jun; 21(3):373-80. PubMed ID: 24915584
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nitinol stent implantation in the superficial femoral artery and proximal popliteal artery: twelve-month results from the complete SE multicenter trial.
    Laird JR; Jain A; Zeller T; Feldman R; Scheinert D; Popma JJ; Armstrong EJ; Jaff MR;
    J Endovasc Ther; 2014 Apr; 21(2):202-12. PubMed ID: 24754279
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nitinol stent implantation vs. balloon angioplasty for lesions in the superficial femoral and proximal popliteal arteries of patients with claudication: three-year follow-up from the RESILIENT randomized trial.
    Laird JR; Katzen BT; Scheinert D; Lammer J; Carpenter J; Buchbinder M; Dave R; Ansel G; Lansky A; Cristea E; Collins TJ; Goldstein J; Cao AY; Jaff MR;
    J Endovasc Ther; 2012 Feb; 19(1):1-9. PubMed ID: 22313193
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and efficacy of the EPIC™ nitinol vascular stent system for the treatment of lesions located in the superficial femoral artery: prospective and multicentric trial.
    Nasser F; Kambara A; Abath C; Cavalcanti D; Barros I; Pires N; Rivera M; Neser A; Ingrund J; Burihan M; Silveira P; Galego G; Bortoluzzi C; Franklin R; Bosiers M; Deloose K; Razuk A; Caffaro R; Karakhanian WK; Park J; Lopes C; Pinto D; Bez L; Lopes R; Mourão A; Kleinsorge G
    J Cardiovasc Surg (Torino); 2017 Jun; 58(3):409-415. PubMed ID: 25731858
    [TBL] [Abstract][Full Text] [Related]  

  • 7. SUMMIT registry: one-year outcomes after implantation of the EPIC self-expanding nitinol stent in the femoropopliteal segment.
    Werner M; Piorkowski M; Thieme M; Nanning T; Beschorner U; Rastan A; Zeller T; Scheinert D
    J Endovasc Ther; 2013 Dec; 20(6):759-66. PubMed ID: 24325691
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Primary stenting of femoropopliteal atherosclerotic lesions using new helical interwoven nitinol stents.
    Chan YC; Cheng SW; Ting AC; Cheung GC
    J Vasc Surg; 2014 Feb; 59(2):384-91. PubMed ID: 24461862
    [TBL] [Abstract][Full Text] [Related]  

  • 9. First clinical experience with the Innova versus the Protege EverFlex self-expanding bare metal stents in superficial femoral artery occlusions.
    Gabrielli R; Rosati MS; Chiappa R; Millarelli M; Marcuccio L; Siani A; Caselli G
    Thorac Cardiovasc Surg; 2015 Mar; 63(2):158-63. PubMed ID: 25602844
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Three year results of endovascular therapy with a new generation nitinol stent for femoro-popliteal artery lesions - a single-center outcome analysis of a subcohort of MISAGO 2 study.
    Kralj I; Boos I; Müller-Bühl U
    Vasa; 2013 Sep; 42(5):340-9. PubMed ID: 23989069
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Incidence and the clinical impact of stent fractures after primary stenting for TASC C and D femoropopliteal lesions at 1 year.
    Davaine JM; Quérat J; Guyomarch B; Brennan MÁ; Costargent A; Chaillou P; Patra P; Gouëffic Y
    Eur J Vasc Endovasc Surg; 2013 Aug; 46(2):201-12. PubMed ID: 23773773
    [TBL] [Abstract][Full Text] [Related]  

  • 12. French multicenter experience with the GORE TIGRIS Vascular Stent in superficial femoral and popliteal arteries.
    Sibé M; Kaladji A; Boirat C; Cardon A; Chaufour X; Bossavy JP; Saint-Lebes B
    J Vasc Surg; 2017 May; 65(5):1329-1335. PubMed ID: 28222987
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Primary stenting of the superficial femoral and popliteal artery.
    Dearing DD; Patel KR; Compoginis JM; Kamel MA; Weaver FA; Katz SG
    J Vasc Surg; 2009 Sep; 50(3):542-7. PubMed ID: 19540706
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Stent placement in the superficial femoral and proximal popliteal arteries with the innova self-expanding bare metal stent system.
    Powell RJ; Jaff MR; Schroë H; Benko A; Diaz-Cartelle J; Müller-Hülsbeck S
    Catheter Cardiovasc Interv; 2017 May; 89(6):1069-1077. PubMed ID: 28296239
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Predictors of restenosis in the use of helical interwoven nitinol stents to treat femoropopliteal occlusive disease.
    Chan YC; Cheng SW; Cheung GC
    J Vasc Surg; 2015 Nov; 62(5):1201-9. PubMed ID: 26169015
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Superficial femoral artery TASC D Registry: twelve-month effectiveness analysis of the Pulsar-18 SE nitinol stent in patients with critical limb ischemia.
    Lichtenberg M; Stahlhoff W; Boese D
    J Cardiovasc Surg (Torino); 2013 Aug; 54(4):433-9. PubMed ID: 24013531
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Four-year randomized prospective comparison of percutaneous ePTFE/nitinol self-expanding stent graft versus prosthetic femoral-popliteal bypass in the treatment of superficial femoral artery occlusive disease.
    McQuade K; Gable D; Pearl G; Theune B; Black S
    J Vasc Surg; 2010 Sep; 52(3):584-90; discussion 590-1, 591.e1-591.e7. PubMed ID: 20598480
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of femoropopliteal in-stent restenosis with paclitaxel-eluting stents.
    Zeller T; Dake MD; Tepe G; Brechtel K; Noory E; Beschorner U; Kultgen PL; Rastan A
    JACC Cardiovasc Interv; 2013 Mar; 6(3):274-81. PubMed ID: 23517839
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The use of the GORE® TIGRIS® Vascular Stent with dual component design in the superficial femoral and popliteal arteries at 6 months.
    Piorkowski M; Freitas B; Schmidt A; Bräunlich S; Ulrich M; Schuster J; Bausback Y; Werner M; Scheinert D
    J Cardiovasc Surg (Torino); 2013 Aug; 54(4):447-53. PubMed ID: 24013533
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The impact of sex on angioplasty and primary stenting for femoropopliteal occlusive disease: results of the DURABILITY II trial.
    Tadros RO; Faries PL; Rocha-Singh KJ; Kim Sy; Malik RK; Ellozy SH; Marin ML; Vouyouka AG
    Ann Vasc Surg; 2014 Jan; 28(1):1-9. PubMed ID: 24189009
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 79.